![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Author: Korhonen Matti Jolkkonen Jukka
Publisher: Future Medicine
ISSN: 1746-0751
Source: Regenerative Medicine, Vol.8, Iss.2, 2013-03, pp. : 93-95
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Cannabinoids for epilepsy: What do we know and where do we go?
EPILEPSIA, Vol. 59, Iss. 2, 2018-02 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Torcetrapib and atherosclerosis: what happened and where do we go from here?
By Toth Peter P
Future Lipidology, Vol. 2, Iss. 3, 2007-06 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Whither lung EIT: Where are we, where do we want to go and what do we need to get there?
By Adler Andy Amato Marcelo B Arnold John H Bayford Richard Bodenstein Marc Böhm Stephan H Brown Brian H Frerichs Inéz Stenqvist Ola Weiler Norbert Wolf Gerhard K
Physiological Measurement, Vol. 33, Iss. 5, 2012-05 ,pp. :
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
![](/images/ico/ico_close.png)
![](/images/ico/ico5.png)
Safeguarding immune globulin recipients against hemolysis: what do we know and where do we go?
TRANSFUSION, Vol. 55, Iss. S2, 2015-07 ,pp. :